EUVIMEDEUVIMED entdecken
LeserbriefVergleichsstudie

Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

Callie Berkowitz, Samuel Wilson, Nigel S Key, Patrick Ellsworth

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.04.027 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Callie Berkowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Ca…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Novo Nordisk Haemophilia Foundation, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsAntibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIIIThrombosisHumansHemophilia ARisk FactorsUnited StatesUnited States Food and Drug Administration

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, HumanizedemicizumabFactor VIII

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA.
  • Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA. Electr…

Förderung

  • Novo Nordisk Haemophilia Foundation
  • Novo Nordisk

Zitieren

APA

Berkowitz, C., Wilson, S., Key, N. S., & Ellsworth, P. (2024). Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.04.027

Vancouver

Berkowitz C, Wilson S, Key NS, Ellsworth P. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.04.027

BibTeX
@article{Berkowitz2024,
  author = {Berkowitz, Callie and Wilson, Samuel and Key, Nigel S and Ellsworth, Patrick},
  title = {Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.04.027}
}
Kostenlos starten →